Peptide Mimotope Optimization

Zolbetuximab (IMAB362) is a chimeric monoclonal antibody that showed promising results in the treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma and is currently evaluated in phase III studies (Sahin et al. Ann. Oncol. 2021. PMID: 33610734). 
Peptidic mimotopes for the ELISA-based detection of IMAB362 in biological samples were developed. Initial hits were identified using phage display and optimized with the help of structure-activity relationship analysis on peptide microarrays. The optimized peptides showed binding constants in the low nanomolar to picomolar range - an improvement by a factor of up to 30 compared to the initial hits. The best mimotope (apparent KD = 0.15 nM) was successfully used for the ELISA-based quantification of IMAB362 in samples from a mouse pharmacokinetic study.



  • Peptide microarrays enable rapid mimotope optimization for pharmacokinetic analysis of the novel therapeutic antibody IMAB362
    Schnatbaum et al., Biotechnol. J. (2014) - PMID: 24497417 
  • Rapid Mimotope Optimization for Pharmacokinetic Analysis of the Novel Therapeutic Antibody IMAB362
    Daneshdar et alAppNote (2014)


  • BioNTech AG, Mainz (M. Daneschdar, H.U. Schmoldt)
  • Johannes Gutenberg-University Mainz
  • TRON, Mainz
  • Ganymed Pharmaceuticals AG, Mainz

Check our list of products, click and go.

Get a quote